Eisai and UCL ready clinical study for antibody aimed at Alzheimer’s

Cellltrion & iProgen Biotech to develop series of novel ADCs
Credit: Shutterstock.com/ Pressmaster

Japan’s Eisai has together with University College London commenced preparations for Phase I clinical studies in Alzheimer’s disease for novel anti-tau antibody E2814.

Discovered through joint research, E2814 is an anti-tau monoclonal antibody which is designed to slow the progression of Alzheimer’s disease and other tauopathies*.

Further, the research collaboration, agreed in 2012 for an initial period of six years, has been extended for a further 5 years to 2023.

It was established as part of Eisai’s Open Innovation strategy to collaborate with leading researchers in order to translate new research findings into innovative treatments for patients with neurodegenerative diseases.

E2814 is one outcome out of a portfolio of projects established during the first phase of the collaboration with UCL.

Professor Alan Thompson, Dean of UCL Faculty of Brain Sciences, said: “This unique research partnership brings together UCL’s world-class academic research capabilities with the drug discovery expertise of industry.

“These results highlight the success of bringing together such complementary expertise.”